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Abstract
Background: Recruitment is often a bottleneck in secondary prevention trials in Alzheimer disease (AD).
Furthermore, screen-failure rates in these trials are typically high due to relatively low prevalence of AD pathology
in individuals without dementia, especially among cognitively unimpaired. Prescreening on AD risk factors may
facilitate recruitment, but the efficiency will depend on how these factors link to participation rates and AD
pathology. We investigated whether common AD-related factors predict trial-ready cohort participation and
amyloid status across different prescreen settings.
Methods: We monitored the prescreening in four cohorts linked to the European Prevention of Alzheimer
Dementia (EPAD) Registry (n = 16,877; mean ± SD age = 64 ± 8 years). These included a clinical cohort, a research in-
person cohort, a research online cohort, and a population-based cohort. Individuals were asked to participate in the
EPAD longitudinal cohort study (EPAD-LCS), which serves as a trial-ready cohort for secondary prevention trials.
Amyloid positivity was measured in cerebrospinal fluid as part of the EPAD-LCS assessment. We calculated
participation rates and numbers needed to prescreen (NNPS) per participant that was amyloid-positive. We tested if
age, sex, education level, APOE status, family history for dementia, memory complaints or memory scores, previously
collected in these cohorts, could predict participation and amyloid status.
Results: A total of 2595 participants were contacted for participation in the EPAD-LCS. Participation rates varied by
setting between 3 and 59%. The NNPS were 6.9 (clinical cohort), 7.5 (research in-person cohort), 8.4 (research online
cohort), and 88.5 (population-based cohort). Participation in the EPAD-LCS (n = 413 (16%)) was associated with
lower age (odds ratio (OR) age = 0.97 [0.95–0.99]), high education (OR = 1.64 [1.23–2.17]), male sex (OR = 1.56 [1.19–
2.04]), and positive family history of dementia (OR = 1.66 [1.19–2.31]). Among participants in the EPAD-LCS, amyloid
positivity (33%) was associated with higher age (OR = 1.06 [1.02–1.10]) and APOE ɛ4 allele carriership (OR = 2.99
[1.81–4.94]). These results were similar across prescreen settings.
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Conclusions: Numbers needed to prescreen varied greatly between settings. Understanding how common AD risk
factors link to study participation and amyloid positivity is informative for recruitment strategy of studies on
secondary prevention of AD.
Keywords: Prescreening, Amyloid, Secondary prevention trials, Registries, Recruitment, Engagement, Trial-ready
cohort
Background
Recruitment of participants for secondary prevention trials
in Alzheimer disease (AD) is challenging, which can cause
substantial delays in study completion [1, 2]. The target
population for these types of clinical trials typically
comprises of individuals without signs of dementia, and with
evidence of amyloid pathology [3]. Clinical trial screening of
these mildly symptomatic or asymptomatic participants is
accompanied by large numbers of screen failures [1]. The
solution may be to introduce low-burden prescreening steps,
which would limit the screening efforts to individuals with
an increased prospect of enrolment into the study [4–7].
However, there is little empirical evidence on prescreening
for secondary prevention trials and whether the efficacy de-
pends on recruitment setting [8–11].
The European Prevention of Alzheimer Dementia (EPAD)
Registry was set up as a virtual registry from existing cohorts
[12]. The purpose was to enable recruitment and preselec-
tion of individuals for participation in the EPAD longitudinal
cohort study (EPAD-LCS) [13], which also serves as a trial-
ready cohort for the EPAD secondary prevention trials [14].
Data on several AD-related factors were available in these
existing cohorts, including age, sex, education, APOE geno-
type, family history of dementia, subjective cognitive decline
(SCD), and memory tests, as well as on common exclusion
criteria. Furthermore, unlike in most trials, where a partici-
pant contacts a site following advertisements, in EPAD, re-
searchers invited participants from the cohorts in the EPAD
Registry into the EPAD-LCS. This approach allowed for in-
vestigation of how AD risk factors related to the participa-
tion rate, an important consideration for the feasibility
assessment of recruitment strategies. The recruitment set-
tings linked to the registry include memory clinics, online
and in-person brain research cohorts, and population-based
cohorts, thereby offering the opportunity to compare them.
We assessed participation rates across different recruitment
settings and provide a number needed to prescreen (NNPS)
to identify one eligible and amyloid-positive individual. We
also tested the AD-related factors as predictors for participa-
tion in the EPAD-LCS and for amyloid positivity.
Methods
Population
The analysis included participants from the first four co-
horts that were linked to the EPAD Registry. The French
Trial Registry in Toulouse selected patients referred by
GPs and self-referral from memory clinics [15]. Inclu-
sion criteria were as follows: interest in clinical trials,
available study partner, and no obvious exclusion criteria
for clinical trials. Data from 195 participants without de-
mentia, with visits between July 2016 and February 2018,
had been linked to the EPAD Registry. The ALFA Study
included cognitively unimpaired individuals who
expressed interest in participating in AD research and
data of 2595 participants aged over 50 years, with first
visits in 2013 and 2014, were linked to the EPAD Regis-
try [16]. Generation Scotland (GS) was a population-
based study which collected data between 2006 and
2011 in Scotland on randomly drawn individuals with a
relative to co-enrol [17]. Its aim was to create a resource
of human biological samples and information for med-
ical research, and data on 13,681 participants aged over
50 years, without a known diagnosis of dementia, were
linked to the EPAD Registry. The pilot ‘hersenonder-
zoek.nl’ (pilotHO.nl) was a web-based registry with the
aim of recruiting people from the general public for
brain research and ran from Sept 2016 to Sept 2017
when the final version of the registry was launched. This
pilot registry had 412 participants, age over 50 years and
without a self-reported diagnosis of dementia, linked to
the EPAD Registry.
EPAD Registry selection and prescreening process
The enrolment process for the EPAD-LCS consisted of
four steps. In step 1, participants were preselected from
the four cohorts using algorithms in the EPAD Registry
online tool [18], based on different combinations of age,
sex, diagnosis of mild cognitive impairment (MCI),
APOE genotype, SCD, memory test scores, and/or family
history for dementia, available in the parent cohort
(Table 1). Flexible algorithms were tailored to each of
the cohorts, and adjusted if the number of individuals
meeting the algorithmic criteria was low. The algorithms
selected individuals older than 50 years across an AD de-
mentia risk spectrum [13]. These included those with
low and medium risk for AD to reach the recruitment
targets for the study, as well as to avoid AD risk status
disclosure by invitation. In step 2, the cohorts’ investiga-
tors checked eligibility of selected individuals, using data
from their databases. These criteria included the EPAD
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in- and exclusion criteria, which involve absence of dis-
orders that could interfere with trial participation, ab-
sence of dementia, and openness to potentially
participate in intervention studies and receive disclosure
[13]. In three of the cohorts, preselected individuals were
then approached by telephone for participation. The
population-based cohort GS sent an opt-in letter. In step
3, the EPAD sites performed a telephone screen to check
eligibility among those who expressed interest in partici-
pating. Prescreen failures during the first 3 steps were
categorised as ‘matching an exclusion criterion’, ‘no
interest in participation in the study’, ‘not returning the
opt-in letter’, ‘other reason, not specified’ [12]. In step 4,
participants visited a site and enrolled in the EPAD-LCS
for a screening/baseline visit, after which eligibility was
confirmed and amyloid status was determined [13].
Data collected as part of the EPAD-LCS
From the EPAD-LCS baseline visit, we used clinical
information, i.e., the CDR sum of boxes (CDR-SOB)
and Mini-Mental State Examination (MMSE); struc-
tural MR imaging visual rating scales, i.e., the medial
temporal atrophy scale (MTA) mean score and Faze-
kas deep score of white matter hyperintensities. From
the cerebrospinal fluid (CSF) analysis, we used Elecsys
Aβ1–42, total tau, and phosphorylated tau values, and
from the blood analyses, for some participants, APOE
ɛ4 genotype. For a full description of the EPAD-LCS
protocols, we refer to [13].
Predictors
The predictors as collected in the cohorts linked to
the Registry were as follows: age, sex, education level
(low to normal or high), APOE genotype (ɛ4 non-
carrier or carrier), presence of family history for
dementia, presence of SCD, and a low score on a de-
layed recall memory test (z-score < − 1.28, details on
definitions of variables Supplement, legend Table 1).
All cohorts had data available on demographics. SCD
data was present in all cohorts, except GS. APOE
genotype was available in the ALFA Study, GS, and a
subset of pilotHO.nl. Family history and memory test
scores were available for all participants of the ALFA
Study and GS, and for the majority in the Toulouse
Registry and pilotHO.nl. The definitions of the pre-
dictors were as follows: high education was 14 years
or more in Toulouse Registry, the ALFA Study, and
GS, and in pilotHO.nl a score of 6 or more on the
Verhage scale, equivalent to college or university level
[19]. Subjective cognitive decline: presence of memory
complaints in the absence of impairment on cognitive
tests (Toulouse Registry); a positive answer on the
question whether the participant memory had com-
plaints (ALFA study), a positive answer on the ques-
tions whether the participant memory had complaints
and worries about their memory (pilotHO). Low
memory delayed recall z-score < − 1.28 on the FCSRT
delayed recall (Toulouse), the memory binding test
(ALFA study), the Wechsler logical memory - delayed
recall (GS), and the Muistikko-test (pilotHO).
Table 1 Baseline available data and characteristics of cohorts
Toulouse
Registry
ALFA Generation
Scotland
pilotHO.nl
Setting Memory clinic In-person
research cohort
Population-
based
Online research cohort
N 195 2589 13,681 412
Age, year 68 (7) 60 (6) 64 (9) 65 (9)
Male, n (%) 56 (29%) 962 (37%) 5399 (39%) 155 (38%)
Highly educated, n (%) (n = 15,239)* 97 (60%) 1225 (47%) 4860 (40%) 313 (77%)
APOE ɛ4 genotype, n (%) (n = 16,185) NA 872 (34%) 3695 (28%) 84 (31%)
Family history for dementia, n (%) (n = 16,844) 131 (71%) 2470 (95%) 1386 (10%) 193 (50%)
Subjective cognitive decline, n (%) (n = 3175)^ 151 (83%) 312 (12%) NA 81 (20%)
% low memory, n (%) (n = 16,420)$ 17 (15%) 242 (9%) 1684 (12%) 20 (9%)
Diagnosed with MCI, n (%)# 13 (7%) 0 3 (0%) 4 (1%)
Estimated amyloid-positive individuals based on [4], taking into account
age-bins, n (%) &
~ 40 (22%) ~ 430 (17%) ~ 2680 (20%) ~ 80 (20%)
Legend: * high education: Toulouse Registry: > = 14 years; ALFA Study: > = 14 years; GS: > = 14 years; pilotHO.nl: > = 6 on the Verhage scale. ^SCD: Toulouse
Registry: physician diagnosis and MCI patients excluded; ALFA Study: memory complaints question; pilotHO.nl: questions on memory complaints with worries;
$Low memory delayed recall z-score < − 1.28: Toulouse Registry: FCSRT delayed recall, normalised by formula (score-11)/2, at raw score cut-off < 9; ALFA Study:
memory binding test, normalised to sample, at raw score cut-off < 18; GS: Wechsler logical memory - delayed recall was normalised, at raw score cut-off < 9;
pilotHO.nl: online Muistikko-test, normalised to sample, at raw score cut-off < 9. #MCI: Toulouse Registry: physician diagnosis; pilotHO.nl and Generation Scotland
self-report. In the ALFA study no MCI patients were enrolled. &Formula based on Janssen et al. [4] (N age bin 50 to 57.5 years) × 12.9% + (N age bin 57.5 to 62.5
years) × 15.8% + (N age bin 62.5 to 67.5 years) × 19.2% + (N age bin 67.5 to 72.5 years) × 23.1% + (N age bin 72.5 to 77.5 years) × 27.6% + (N age bin 77.5 to 82.5
years) × 32.6% + (N age bin 82.5 years and older) × 38%
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Outcomes
The first outcome measure was enrolment into the
EPAD-LCS, indicating participation in a screening/base-
line visit. The second outcome was amyloid positivity,
defined as CSF Aβ1–42 below 1098 pg/mL [20–22], for
participants who completed and passed the eligibility
checks of the EPAD-LCS screening visit.
Statistical analysis
Participation rate was defined as the percentage of
individuals who underwent the EPAD-LCS screening
visit out of the individuals approached for participa-
tion in the EPAD-LCS. The NNPS was defined as
the ratio between the number of individuals con-
tacted for participation and the number of individ-
uals that passed baseline visit classified as amyloid
positive. The number needed to screen (NNS) was
the ratio between the number of individuals with
baseline data and the number of individuals that
passed screening visit who were classified as amyl-
oid positive. To test the association between AD
risk factors (predictors) and participation into the
EPAD-LCS, and among those enrolled, between AD
risk factors and amyloid positivity, we applied uni-
variate logistic mixed models with a random term
for cohort and fixed term for the predictor. Age was
centred at 65. Explorative analyses included analyses
stratified now by cohort using univariate logistic re-
gression models. Additionally, as a second step, all
significant predictors for either of the two outcomes
were combined in two final multivariate models to
summarise the results. Statistical analyses were per-
formed in R version 3.4.2, using packages ‘lme4’ and
‘lmerTest’ [23, 24].
Results
The four cohorts linked to the EPAD Registry in-
cluded 16,877 participants. The participants were on
average 64 (SD = 8) years old and 39% were male, and
expected amyloid positivity was calculated to be 19%
based on a published meta-analysis [4] (Table 1). Fig-
ure 1 and Table 2 describe the recruitment flow of
participants to enrolment and amyloid measurement
in the EPAD-LCS between May 2016 and March 2018.
Table 3 presents clinical, imaging, and CSF markers of the
EPAD-LCS baseline visit for participants recruited from
each of the cohorts, stratified by amyloid status.
From the EPAD Registry, 3009 individuals were
preselected for participation in the EPAD-LCS and
2595 individuals were contacted, of whom 413 (16%)
agreed to participate and were eligible for the
EPAD-LCS screening visit. To prevent contacting in-
dividuals matching exclusion criteria for the EPAD-
LCS, most cohorts conducted a database check. This
was most efficient in the Toulouse registry (100%).
Of the individuals with exclusion criteria in the
ALFA Study and in pilotHO.nl, 75% (110/147) and
55% (24/53) were found during the database check,
respectively. Participation rate varied by setting; in
the Toulouse Registry, it was 59%, in the ALFA
Study 56%, in GS 3%, and in pilotHO.nl 46%. The
primary reasons for not participating were not
returning the opt-in leaflet (67%), no interest (16%),
and other reasons (13%). Of the 324 participants
who had passed the eligibility checks during EPAD-
LCS screening visit and had their amyloid status
available, 107 (33%) participants were amyloid posi-
tive. The total number of amyloid-positive individ-
uals was similar between cohorts (Toulouse Registry
Fig. 1 Prescreening to enrolment: flow from EPAD Registry to EPAD trial-ready cohort. Legend: CSF = cerebrospinal fluid; EPAD = European
Prevention of Alzheimer Dementia
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n = 23, ALFA Study n = 36, GS n = 22, pilotHO.nl
n = 26). However, the NNPS to find one eligible
amyloid-positive participant varied; in the Toulouse
Registry, it was 6.9, in the ALFA Study 7.5, in GS 88.5,
and in pilotHO.nl 8.4. Among individuals enrolled in the
EPAD-LCS, the NNS in order to find one amyloid-
positive individual passing the screening visit was between
3.0 and 3.8 in all settings (Table 2).
Predictors for participation rate
The AD risk factors that were univariately associated
with participation in the EPAD-LCS, for all cohorts
Table 2 Recruitment flow from EPAD Registry by recruitment setting
Cohorts Total
Toulouse Registry ALFA Study Generation Scotland pilotHO.nl
Setting Memory clinic In-person
research cohort
Population-based Online research cohort
Step 1 Selection by PREPAD tool 169 618 1947 275 3009
Step 2 Not eligible based database check 11 347 1 55 414
• Exclusion criterion 10 110 1 29 150
• Other 1 237 0 26 264
Number selected for step 3
(% from step 1)
158 (93%) 271 (44%) 1946 (100%) 220 (80%) 2595 (86%)
Step 3 Not eligible after contacting participant 65 119 1879 119 2182
• No interest 64 24 178 83 349
• No response to letter NA NA 1470 NA 1470
• Exclusion criterion 0 37 12 24 73
• Other 1 58 219 12 290
Number selected for step 4
(% from step 3)
93 (59%) 152 (56%) 67 (3%) 101 (46%) 413 (16%)
Step 4 EPAD-LCS screening visit 70 137 67 88 362
Eligible & CSF Aβ1–42 analysed 64 124 61 75 324
• CSF Aβ1–42 < 1098 pg/mL (positivity) 23 (36%) 36 (29%) 22 (36%) 26 (35%) 107 (33%)
Number needed to screen 3.0 3.8 3.0 3.4 3.4
Number needed to prescreen 6.9 7.5 88.5 8.5 24.3
Legend: in italic the total number of the subset on which percentages are based. Number of individuals unless otherwise specified. CSF cerebrospinal fluid, EPAD-
LCS v500 is the currently available data, quality checked at data lock. N = 51 EPAD screening visit details not yet available. N = 5 CSF results missing. N = 32 screen
failure: 11× other disease/incidental findings/CDR > =1, 18× procedures not possible, 3× investigator decision/no reason provided/no contact possible. Number
needed to screen = N CSF Aβ1–42 positive in step 4 / N eligible and CSF Aβ1–42 analysed in step 4, while the number needed to prescreen = N CSF Aβ1–42
positive in step 4/ N selected for step 3
Table 3 Included participants in EPAD Longitudinal cohort study per recruitment setting
Toulouse Registry ALFA Study Generation Scotland pilotHO.nl
CSF Aβ +ve CSF Aβ normal CSF Aβ +ve CSF Aβ normal CSF Aβ +ve CSF Aβ normal CSF Aβ +ve CSF Aβ normal
n 23 41 36 88 22 39 26 49
Age, year 71 (5) 67 (8)^ 64 (6) 64 (5) 71 (3) 67 (5)# 68 (6) 66 (7)
Male, n (%) 4 (17%) 17 (41%) 23 (64%) 41 (47%) 14 (61%) 23 (57%) 14 (52%) 19 (37%)
MMSE (30–0) 28.0 (2.1) 28.8 (1.7) 28.6 (1.1) 28.7 (1.6) 28.1 (1.6) 28.8 (1.4) 28.4 (1.5) 29.1 (1.3)
CDR-SOB (0–18) 0.74 (0.7) 0.34 (0.5)^ 0.10 (0.3) 0.05 (0.2) 0.15 (0.3) 0.06 (0.2) 0.06 (0.2) 0.02 (0.1)
CSF Aβ1–42, pg/mL 756 (195) 1613 (361)# 823 (191) 1696 (519)# 748 (251) 1769 (411)# 846 (217) 1788 (443)#
CSF P-tau, pg/mL 29 (15) 18 (4.9)$ 21 (15) 17 (7) 19 (9) 21 (12) 21 (10) 17 (5)
CSF T-tau, pg/mL 305 (125) 210 (53)$ 223 (132) 209 (79) 211 (81) 249 (115)* 240 (101) 206 (58)
MTA (0–4) 0.4 (0.5) 0.2 (0.4) 0.2 (0.4) 0.1 (0.3) 0.4 (0.6) 0.1 (0.4) 0.2 (0.4) 0.2 (0.4)
Fazekas (0–3) 1.1 (0.7) 0.8 (0.7) 1 (0.6) 0.8 (0.6) 1.1 (0.9) 0.7 (0.7)^ 0.9 (0.8) 0.9 (0.7)
Legend: MMSE Mini-Mental State Examination, CDR-SOB Clinical Dementia Rating scale- Sum Of Boxes, CSF cerebrospinal fluid, P-tau phosphorylated tau, T-tau
total tau, MTA medial temporal lobe atrophy. Mean (SD) unless otherwise specified. *One outlier at t-tau 792 and p-tau 81. Undetectably low p-tau and t-tau was
set at the detection border of 8 and 80 respectively, Aβ1–42 was extrapolated. Raw p < 0.05 = ^; p < 0.01 = $, p < 0.001 = #
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combined, were lower age (odds ratio (OR): age = 0.97
[0.95–0.99]), high education level (OR = 1.64 [1.23–
2.17]), male sex (OR = 1.56 [1.19–2.04]), and family
history of dementia (OR = 1.66 [1.19–2.31], Table 4,
for AUCs Additional file 1: Table S2). In single co-
horts, participation rates in the Toulouse Registry
were predicted by SCD (OR = 0.29; [0.09–0.76]), in
the ALFA Study by male sex (OR = 2.03 [1.24–3.35]),
in GS by male sex (OR = 1.81 [1.11–3.01]), high edu-
cation (OR = 2.20 [1.34–3.59], and family history
(OR = 2.95 [1.73–4.91], and in pilotHO.nl by age
(OR = 0.96 [0.93–1.00]). As a next step, we combined
the predictor variables age, sex, education, family his-
tory, and APOE in a multivariate model (Fig. 2, Add-
itional file 1: Table S1 and Table S3). Study
enrolment was still associated with age, sex, educa-
tion, and family history (n with all variables = 2322).
Predictors for amyloid positivity
Among all individuals enrolled in EPAD-LCS, amyl-
oid positivity was univariately predicted by older age
(OR = 1.06 [1.02–1.10]) and carrying an APOE ɛ4 al-
lele (OR = 2.99 [1.81–4.94]) (Table 4, for AUCs,
Additional file 1: Table S2). In individual cohorts,
amyloid positivity in the Toulouse Registry was pre-
dicted by higher age (OR = 1.10 [1.01–1.20]), gender
(male OR = 0.30 [0.08–0.96]), APOE ɛ4 (OR = 6.42
[1.93–24.1]), and low memory (OR = 18.90 [2.87–
377]; in the ALFA Study by none; in GS by higher
age (OR = 1.23 [1.08–1.45]) and APOE ɛ4 (OR = 7.20
[2.20–28.77]); and in pilotHO.nl by APOE ɛ4 (OR =
3.34 [1.22–9.48]). In the multivariate model,
including predictor variables age, sex, education,
family history, and APOE, amyloid status was pre-
dicted by age, APOE ɛ4, and weakly by family history
(p = 0.03, n with all variables = 322, Fig. 2, Add-
itional file 1: Table S1 and Table S3).
Discussion
Across settings, participation rates varied, while predic-
tors for participation into the trial-ready cohort and
amyloid positivity were comparable. Among those con-
tacted for participation, enrolment was higher for indi-
viduals who were younger, more educated, or males or
had a family history of dementia, while amyloid positiv-
ity in the trial-ready cohort was only associated with be-
ing older and carrying an APOE ɛ4 allele.
The NNPS to find one amyloid-positive eligible par-
ticipant in the population-based Generation Scotland
study was ten times higher than for those cohorts fo-
cussed on brain disorders, which may be explained by
their willingness to take part in an AD study [25]. Gen-
eration Scotland study visits have been completed, and
the time between the last Generation Scotland study
visit and EPAD recruitment was also longer than for the
other cohorts. In addition, an opt-in letter was sent to
Generation Scotland participants, while other cohorts
contacted individuals by telephone, which may have low-
ered the response [26]. Moreover, the EPAD study site
was at a travel time of 1–3 h from the recruitment re-
gion. Finally, the cohorts from the other settings ex-
cluded persons with known exclusion criteria
beforehand based on data from their cohort database,
which may have decreased later stage prescreen failures.
Still, the number of participants recruited of the large
Table 4 Univariate logistic regression for enrolment and CSF Aβ1–42 positivity in whole sample and stratified by recruitment setting
Sample size Total Toulouse Registry ALFA Study Generation Scotland pilotHO.nl
n = 2595 n = 324 n = 158 n = 64 n = 271 n = 124 n = 1947 n = 61 n = 220 n = 75
Outcome Enrolment* CSF Aβ
+ve^
Enrolment* CSF Aβ +ve^ Enrolment* CSF Aβ
+ve^
Enrolment* CSF Aβ
+ve^
Enrolment* CSF Aβ
+ve^
Aged over 70 years Old 0.97
(0.95–0.99)
1.06
(1.02–1.10)
0.99
(0.94–1.03)
1.10
(1.01–1.20)
0.99
(0.95–1.03)
1.01
(0.94–1.08)
0.97
(0.93–1.01)
1.23
(1.08–1.45)
0.96
(0.93–1.00)
1.03
(0.97–1.11)
Male 1.56
(1.19–2.04)
1.28
(0.81–2.04)
1.17
(0.58–2.42)
0.30
(0.08–0.96)
2.03
(1.24–3.35)
2.03
(0.92–4.60)
1.81
(1.11–3.01)
1.35
(0.47–4.08)
1.13
(0.66–1.94)
2.01
(0.77–5.36)
Highly educated 1.64
(1.23–2.17)
0.89
(0.56–1.42)
1.44
(0.69–2.98)
0.72
(0.25–2.13)
1.42
(0.87–2.31)
1.10
(0.50–2.39)
2.20
(1.34–3.59)
0.66
(0.22–1.88)
1.33
(0.67–2.67)
0.75
(0.24–2.51)
APOE ɛ4 genotype 0.95
(0.70–1.28)
2.99
(1.81–4.94)
NA 6.42
(1.93–24.1)
0.68
(0.41–1.10)
1.72
(0.79–3.86)
1.37
(0.84–2.25)
7.20
(2.2–28.77)
0.92
(0.49–1.72)
3.34
(1.22–9.48)
Family history of
Dementia
1.66
(1.19–2.31)
1.58
(0.83–3.00)
1.04
(0.50–2.15)
0.95
(0.31–2.98)
1.12
(0.38–3.23)
NA# 2.95
(1.73–4.91)
2.90
(0.97–8.96)
1.27
(0.73–2.22)
1.94
(0.68–6.09)
Subjective cognitive
decline
0.86
(0.58–1.27)
1.51
(0.88–2.61)
0.29
(0.09–0.76)
2.93
(0.67–20.6)
0.79
(0.41–1.55)
1.15
(0.38–3.22)
NA NA 1.16
(0.62–2.15)
1.73
(0.62–4.79)
Low memory score 0.84
(0.60–1.17)
1.47
(0.82–2.61)
0.63
(0.21–1.87)
18.90 (2.87–
377)
0.95
(0.56–1.64)
1.29
(0.55–2.96)
0.78
(0.44–1.31)
0.95
(0.28–3.02)
0.91
(0.29–2.83)
0.58
(0.03–4.98)
Odds ratio (95% CI); CSF cerebrospinal fluid. Italics is significant p < 0.05. *Odds ratio for participating baseline/screening visit after invitation. ^Odds ratio for
amyloid positivity among those included in EPAD-LCS. #Infinite, not possible to calculate a value
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population-based Generation Scotland cohort was com-
parable to the bespoke cohorts, suggesting that there is
scope and willingness within these types of cohorts to
participate in dementia-related intervention studies.
Lower participation at older ages and higher participa-
tion for both highly educated participants and those with
a family history of dementia are in line with studies with
dementia patients and online registers [9, 10, 27–29].
Barriers for older individuals to participate may include
morbidities, difficulties to travel, and not having a study
partner. The higher participation rate of males was un-
expected, as many research studies have lower male than
female participation [9, 10, 30, 31].
The predictors for amyloid positivity, i.e. age and
APOE, were as expected and in line with previous
studies, including an EPAD-LCS full dataset analysis
[4, 6, 32, 33]. Low memory scores, in contrast, were
only a significant predictor for amyloid positivity in
the memory clinic cohort and the presence of SCD
did not predict amyloid positivity in our sample. As
low memory scores were the best predictor for
amyloid positivity in the memory clinic setting,
memory tests may form a useful prescreen in this
situation. An explanation for the discrepancy with
previously reported associations of these factors
with amyloid status could be the non-standardised
test data and could possibly show better predictive
effects with the use of tailored sensitive tests and
questionnaires [9, 11, 32, 34–37].
The prevalence of amyloid positivity in those enrolled
in the EPAD-LCS was 33%. This prevalence was
enriched around 1.5 times compared to the estimated
prevalence in the whole cohorts based on a meta-
analysis of prevalence in cognitively normal individuals
[4]. The limited increase in prevalence of amyloid posi-
tivity could be explained by the fact that the variables
available for prescreening each have a modest predictive
accuracy for amyloid positivity [4, 6]. Another explan-
ation is that low- and intermediate-risk individuals were
selected from the cohorts in order to prevent risk dis-
closure by invitation and to have sufficient enrolment in
the EPAD-LCS.
An advantage of our approach compared to other re-
cruitment strategies such as media campaign advertise-
ment is that the use of existing data helped to exclude
individuals with known exclusion criteria for secondary
prevention trials. However, no direct comparison of effi-
ciency relative to other prescreening strategies (e.g. ad-
vertising) could be made. A disadvantage of our
approach is that consent to re-contact needs to be
present in the cohorts and some costs are involved in
the prescreening. In addition, cohorts become depleted,
as shown for the smaller cohorts in our study. Future
projects could involve direct comparisons between re-
cruitment strategies and focus on cost and effort moni-
toring and comparison. Another important factor when
recruiting from collaborating studies, as well as in the
gathering of a ‘trial-ready cohort’ is the aspect of time
and cohort maintenance costs of both the recruitment
cohorts and EPAD-LCS, but substantial. As AD is a pro-
gressive disorder, the time between testing in a parent
cohort and time of selection may be important. Future
work on the EPAD-LCS and similar projects needs to
optimise the costs and efforts of maintaining a trial
ready cohort. This should also involve monitoring the
rate at which individuals become ineligible over time, for
example because they develop comorbidities that are ex-
clusion criteria.
A limitation is that the analyses were done with the
risk factors available in each cohort, such that not all
risk factors were available in all cohorts for all individ-
uals. Also, the use of the available data and adaptation to
Fig. 2 Multivariate model for enrolment and amyloid positivity. Legend: EPAD-LCS = EPAD longitudinal cohort study (trial-ready cohort). APOE =
apolipoprotein E gene. Shown effect sizes are: Age per 5 years older at baseline, APOE ɛ4 in contrast to no APOE ɛ4, male in contrast to female,
highly educated in contrast to low or normal level educated, family history for dementia positive in contrast to family history for
dementia reported
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local standard procedures meant that there was variabil-
ity in the operationalisation of variables. Secondly, algo-
rithms for preselection in the EPAD Registry tool
included predictor variables of the current study. Still,
that is unlikely to influence the association between each
of the risk factors and participation rate as multivariate
models yielded similar results. Additionally, cohorts were
different from each other in more than one factor, such
as sample size, population characteristics, and communi-
cation style. Therefore, differences in recruitment rate
may be explained by several factors. Despite the differ-
ences, participation rate was associated with similar AD
risk factors across cohorts. Finally, we have now studied
the participation in a trial-ready cohort, but enrolment
into an actual clinical trial might give different results,
depending on study-specific in- and exclusion criteria
and trial design [38]. Strengths of our study are the pro-
spective prescreening and the large sample in which
amyloid-testing was performed.
Our comparison of common AD risk factors for
their association with participation rate and amyloid
positivity has several implications for prescreening
strategies for secondary prevention trials aimed at in-
dividuals with amyloid pathology. Age was a rela-
tively strong predictor for amyloid positivity.
However, we also showed that elderly individuals
were less likely to participate in the study, which
would limit the prescreening efficiency of age for
amyloid positivity. Therefore, addressing barriers for
older individuals to participate could increase re-
cruitment of eligible participants [29, 39]. Carrying
an APOE ɛ4 allele was also a strong predictor of
amyloid status, but as published before, the disadvan-
tage is that around 40% of amyloid-positive individ-
uals are APOE ɛ4 non-carriers [40]. The prevalence
of APOE ɛ4 positivity is around 20–30% and this may
therefore not be optimal for prescreening in a small
cohort. Disclosure of genotype could also be an issue
[10, 41]. These limitations may be overcome by using
a family history for dementia as a prescreener. The
advantage of this risk factor is the association with a
greater enrolment rate, but the disadvantage is that
its association with amyloid positivity is weak and the
prevalence in the general population low. Subtle
memory decline or concerns were not a useful pre-
screen for amyloid status in our study, but more spe-
cific tests or questionnaires may perform better [11,
42, 43]. A promising alternative may be blood tests
for amyloid [5, 44, 45]. With a sensitive threshold,
such a test has the advantage to more effectively pre-
screen relatively younger individuals, who often com-
prise a large part of a registry population and are
more likely to participate, but have a low prevalence
of amyloid pathology.
Conclusions
We found that enrolment rates show major differences
between cohorts, although predictors for participation
were similar. The provided NNPS to find one eligible
amyloid-positive participant are indicators that future re-
cruitment strategies can relate to. The findings highlight
considerations of clinical trial investigators, balancing a
gain in the ease of recruitment with potentially reducing
the generalizability of the trial. Measures to increase effi-
ciency for recruitment for secondary prevention trials
may include using prospective registries with continuous
enrolment of participants, adding a prescreening step
with sensitive measures, such as a blood test, and ad-
dressing barriers for older and lower-educated individ-
uals to participate.
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